Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab

Mediterranean Journal of Hematology and Infectious Diseases
Wonhee SoJohn N Greene

Abstract

Blinatumomab is an anti-CD19 immunotherapy approved for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) with significantly increased survival rate. While blinatumomab showed lower rates of infection, neutropenia and mucosal barrier injury versus chemotherapy, its infection risks are not well described. All patients who received blinatumomab for ≥ seven days at an academic cancer center from May 2015 to April 2017 were included. Patient characteristics pertinent to infectious risks and complications were examined. Twenty patients with refractory (25%), relapsed (70%), or remitted (5%) B-ALL who received a total of 35 cycles were included. Ten of the 35 cycles were interrupted, none of which were due to infections. Twenty-six infections (n) were observed with lower respiratory (9), gastrointestinal (6) and bacteremia (5) being most common. Compared to patients without nodular, possible mold pneumonia (n=16), patients with nodular pneumonia (n=4) had significantly lower baseline absolute neutrophil count (ANC) (2319 v. 208/μL, p=0.011). There were no differences in baseline characteristics including ANC between bacteremic and non-bacteremic patients. One patient was discharged with no antibacterial prophylaxis since ...Continue Reading

Citations

Jun 12, 2020·Clinical Microbiology Reviews·Joshua S DavisMichael Boyle
Dec 23, 2021·Internal Medicine Journal·Benjamin W TehUNKNOWN Australasian Antifungal Guidelines Steering Committee

❮ Previous
Next ❯

Software Mentioned

SPSS Statistics

Related Concepts

© 2022 Meta ULC. All rights reserved